March 11, 2020 / 12:10 PM / a month ago

BRIEF-Oncternal Therapeutics Announces Interim Clinical Data Update

March 11 (Reuters) - Oncternal Therapeutics Inc:

* ONCTERNAL THERAPEUTICS ANNOUNCES INTERIM CLINICAL DATA UPDATE, INCLUDING 50% COMPLETE RESPONSE RATE, FOR CIRMTUZUMAB IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH MANTLE CELL LYMPHOMA

* ONCTERNAL THERAPEUTICS INC - COMBINATION OF CIRMTUZUMAB PLUS IBRUTINIB HAS BEEN WELL TOLERATED

* ONCTERNAL THERAPEUTICS- THERE WERE NO DOSE-LIMITING TOXICITIES, NO DISCONTINUATIONS AND NO SERIOUS ADVERSE EVENTS ATTRIBUTED TO CIRMTUZUMAB ALONE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below